CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer

The prospects and challenges of chimeric antigen receptor T cell therapy for head and neck squamous cell carcinoma

“…We congratulate the authors for an interesting paper which introduces the conspectus of CAR-T cell therapy and interprets its implication for HNSCC based on two previous studies on this malignancy. In fact, this issue has been explored in several studies and phase I trials 3 – 12 . They passed over most current evidence and appropriate description and discussion on this issue, probably due to the length in a correspondence.…”

“…Therefore, the purpose of the current correspondence is to evaluate the evidence on CAR-T cell therapy for HNSCC with a detailed description based on studies from literature databases. As presented in Table 1 , there are nine preclinical studies and two phase I trials (NCT03740256, NCT01818323) involving CAR-T cell therapy for HNSCC 3 – 12 . The most common therapeutic target of CAR-T cells was EGFR (four studies), followed by HER2, B7-H3, CD44v6, CD70, CD98, HLA-G, ERBb2, and MUC1.…”